Page last updated: 2024-08-24

tenofovir and Dermatoses

tenofovir has been researched along with Dermatoses in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Corciulo, C; Cronstein, B; Feig, JL; Liu, H; Mediero, A; Perez-Aso, M; Picard, L; Wilder, T; Zhang, J1
Brieva, J; Kosche, C; Nardone, B; Palella, FJ; Para, A; West, DP1
Martin, L1

Reviews

1 review(s) available for tenofovir and Dermatoses

ArticleYear
[What's new in dermatological treatments?].
    Annales de dermatologie et de venereologie, 2010, Volume: 137 Suppl 4

    Topics: Adenine; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cyclosporine; Dermatofibrosarcoma; Dermatologic Agents; Dermatology; Drug Therapy, Combination; Etanercept; Follow-Up Studies; Gels; HIV Infections; Humans; Imatinib Mesylate; Immunoglobulin G; Immunosuppressive Agents; Ipilimumab; Melanoma; Neoplasm Staging; Organophosphonates; Piperazines; Psoriasis; Pyrimidines; Receptors, Tumor Necrosis Factor; Skin Diseases; Skin Neoplasms; Survival Analysis; Tenofovir; Treatment Outcome; Ustekinumab

2010

Other Studies

2 other study(ies) available for tenofovir and Dermatoses

ArticleYear
The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin.
    PloS one, 2017, Volume: 12, Issue:11

    Topics: Adenosine; Adenosine Triphosphate; Animals; Antiviral Agents; Connexins; Disease Models, Animal; Dose-Response Relationship, Drug; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Skin; Skin Diseases; Tenofovir

2017
Incidence of cutaneous adverse events after exposure to tenofovir-emtricitabine in HIV-uninfected vs HIV-infected patients: pharmacovigilance within a large Midwestern U.S. patient population from the Research on Adverse Drug events And Reports program.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:12

    Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Midwestern United States; Pharmacovigilance; Skin Diseases; Tenofovir; Young Adult

2019